Global Allergic Asthma Disease Market – Industry Trends and Forecast to 2029

Allergic Asthma Disease Market Analysis and Size

The global allergic asthma disease market is expected to witness significant growth during the forecast period. The growth of allergic asthma disease market is rise by the high prevalence of indoor as well as outdoor allergen that causes asthma disease.  The allergic asthma disease market growth is immensely impacted by the sudden outbreak of COVID-19 all across the globe.

 Data Bridge Market Research analyses a growth rate in the global allergic asthma disease market in the forecast period 2022-2029. The expected CAGR of global allergic asthma disease market is tend to be around 3% in the mentioned forecast period. The market was valued at USD 7 billion in 2021, and it would grow upto USD 8.87 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

When the asthma is caused due to certain allergen such as tobacco smoke, dust mites, pollen, or air pollution, it results in allergic asthma. The typical sign and symptoms of the allergic asthma are recurrent episodes of breathlessness and wheezing.           

Allergic Asthma Disease Market Scope and Segmentation

Global Allergic Asthma Disease Market Dynamics

Drivers

• Increased Clinical Acquisitions

Major market players in the industry are strategically expanding to strengthen their position in the global market. For instance, in May 2019, ASLAN Pharmaceuticals amended its license agreement with CSL Limited (CSL) with an aim to have global rights to develop, manufacture, and commercialize ‘ASLAN004’ for all types of indications. ASLAN004 is a fully human monoclonal antibody that helps trigger allergic asthma symptoms such as wheezing, exacerbations of the disease, coughing, and shortness of breath. 

• Launch of New Drugs

There has been several approvals and launch of novel drugs in the market which boost the market growth during the forecast period. For instance, Teva Pharmaceuticals Industries Limited received U.S. FDA approval in June 2017, for its two products of asthma inhalers namely; ArmonAirTM RespiClick and AirDuoTM Respiclick. These products are very much applicable for adolescent and adult patients who are suffering from asthma. The approved strength of AirDuo is 232/14 mcg, 113/14 mcg, and 55/14 mcg, whereas, the approved strengths of ArmonAir is 232 mcg, 113, mcg, and 55 mcg respectively and recommended as one inhalation twice daily. This boosts the market growth

Opportunities

• Increasing Demand for Retail Pharmacies

Rise in the number of rhinitis therapeutics are delivered through retail pharmacies and rise in the number of retail pharmacies in developed countries create much opportunities for the market growth. In addition to this, patients select retail pharmacies for purchasing drugs, as these are easily accessible.

• Rising Healthcare Expenditure

Since the last few decades, it has been witnessed that global per capita healthcare spending has improved considerably due to rising rate of awareness associated with the availability of treatments and diagnostic methods for treating various diseases. More and more healthcare spending is likely to result in increasing demand for better diagnostic methods, which in turn, create high growth opportunities for market players operating in the treatment of allergic and asthmatic conditions in the global allergic asthma disease market.

 Restraints/Challenges

• Lack of skilled professionals

The lack of qualified personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global allergic asthma disease market over a forecast period.

• High Cost

The huge expenditure associated with the treatment of allergic asthma surely hamper the market growth.

This global allergic asthma disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global allergic asthma disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Allergic Asthma Disease Market Scope

The global allergic asthma disease market is segmented on the basis of drug class, route of administration , distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Inhaled Corticosteroids
• Anticholinergics
• Beta Agonists
• Others

Route of Administration

• Oral
• Inhalation
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Allergic Asthma Disease Market Regional Analysis/Insights

The global allergic asthma disease market is analysed and market size insights and trends are provided by drug class, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global allergic asthma disease market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a positive growth for global allergic asthma disease market throughout the forecasted period due to the presence of key generic pharmaceuticals companies in this region and rise in consumption of tobacco products.

North America dominates the market due to the high prevalence of asthma disease and large availability of treatment options.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Allergic Asthma Disease Market Share Analysis

The global allergic asthma disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global allergic asthma disease market

Key players operating in the global allergic asthma disease market include:

• Pfizer Inc.(U.S.)
• Merck KGaA (Germany)
• Sanofi (France)
• Biocare Medical, LLC (U.S.)
• Lilly (U.S.)
• Teva Pharmaceutical Industries (Israel)
• Bristol-Myers Squibb Company (U.S.)
• GSK plc. (U.K.)
• Bayer AG (Germany)
• Teva Pharmaceuticals Industries Ltd. (Israel)
• Lilly (U.S.)
• AstraZeneca (U.K.)
• Sunovion Pharmaceuticals Inc. (U.S.)
• AbbVie Inc (U.S.)

SKU-53992